DEA Special Registration for Telemedicine: What Providers Need to Do Before December 2026
The telemedicine cliff got pushed back again. The DEA’s Fourth Temporary Extension keeps current prescribing rules in place through December 31, 2026. But that date isn’t as far off as it sounds, and treating it that way is a mistake.
What can you actually do right now?
You can prescribe Schedule II–V controlled substances through audio-video telemedicine without an in-person evaluation first. This works for new patients and existing ones. You need to be properly licensed and DEA-registered. You also need to follow your state’s specific rules on top of the federal ones.
That last part matters more than people think. Several states already require in-person exams for certain substances, no matter what the federal rule allows. The federal flexibility is a floor, not a ceiling. Check your state before you build a workflow around the federal rule alone.
These flexibilities aren’t a permanent fix. They sit alongside two separate permanent rules, one for buprenorphine induction via telemedicine and one for VA continuity-of-care telemedicine, both effective since December 31, 2025. Most general telehealth practices run under the temporary extension, not these two narrower rules. Confirm which one actually applies to you.
Why can’t you just wait for the final rule?
The DEA has proposed a special registration framework for telemedicine, but it isn’t final. No government source has committed to an exact 2026 date beyond the extension itself. That gap is the risk.
Rules that land without warning create bottlenecks. Wait until the last month to convert patients to in-person visits and you’re competing with every other practice doing the same thing. You’ll also be scrambling on documentation requirements nobody’s written yet. Starting early doesn’t commit you to any specific outcome. It just means you’re not caught flat-footed.
What should Phase 1 look like: Audit and Assessment?
Start by counting your active telehealth prescribing volume. How many patients are you treating solely through remote visits right now? Calculate the revenue tied to those patients specifically. Then split them into two groups: who could safely move to a non-controlled alternative, and who genuinely needs a controlled substance with no in-person visit on file. That second group is your priority.
How do you handle Phase 2: In-Person Conversion?
Build your scheduling capacity before you need it, not after. Line up local referral pathways for patients who can’t easily travel to you. Prioritize your conversion list by clinical urgency, not convenience. Document every in-person encounter carefully. If future rules require proof of a prior evaluation, this paperwork is what protects you.
What does Phase 3: Operational Readiness involve?
Build hybrid workflows that separate patients with an in-person record from those without one. Update your scheduling and billing templates to track that distinction automatically. Connect your PDMP access to your EHR so monitoring happens without manual checks. Tell your patients clearly what’s changing and why, and make sure your staff treats these protocols as mandatory, not optional.
Quick Start Checklist
- Inventory: Count every patient receiving controlled substances via telehealth.
- Risk Profile: Sort patients by medical necessity versus convenience.
- Referral Network: Build relationships with local clinics for in-person exams.
- Documentation: Check your EMR templates capture “in-person” status clearly.
- Consult your compliance counsel.
Source
This post is for educational purposes only and does not constitute legal or compliance advice. Consult a qualified attorney or compliance professional before acting on this information.
